• HOME
  •  > 
  • 薬学
  •  > 
  • 雑誌
  •  >  医学と薬学　80/12　2023年12月号

医学と薬学　80/12　2023年12月号

出版社： 自然科学社
発行日： 2023-11-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 虚血性心疾患
電子書籍版： 2023-11-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,760 円(税込)

購入する

目次

  • 特集　虚血性心疾患

    序文
    慢性冠症候群とは
    急性冠症候群の診断と治療
    日本人のエビデンスに基づく冠動脈疾患に対する抗血栓療法
    虚血性心疾患に対する最新の脂質コントロール
    心血管イベント抑制を見据えた血糖コントロール
    冠動脈に有意狭窄のない狭心症（INOCA）

    臨床報告
    　食欲不振を有する低栄養患者に対する人参養栄湯の有用性の検討

    臨床試験
    　レナリドミドカプセル5mg「F」の閉経後健康女性における生物学的同等性試験

    Diagnosis
    　化学発光酵素免疫測定法を用いた高感度Glypican-3測定試薬の開発

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 虚血性心疾患】

P.1143 掲載の参考文献
1) Knuuti J, Wijins W, Saraste A, et al: 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 41:407-477, 2019.
 
2) 日本循環器学会ホームページ:慢性冠動脈疾患診断ガイドライン(2018年改定版), 2019. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_yamagishi_tamaki.pdf
 
3) Newby DE, Adamson PD, Berry C, et al: Coronary CT and 5-year risk of myocardial infarction. N Engl J Med 379:924-933, 2018.
PubMed
4) Gulati M, Levy PD, Mukherjee D, et al: 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heaet Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol 78:e187-e285, 2021.
 
5) 日本循環器学会ホームページ:2021年度活動 2022年JCSガイドライン フォーカスアップデート版 安定冠動脈疾患の診断と治療ガイドライン(2022年改定版), 2022. https://www.j-circ.or.jp/cms/wp-content/uploads/2022/03/JCS2022_Nakano.pdf
 
6) Maron DJ, Hochman JS, Reynolds HR, et al: Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 382:1395-1407, 2020.
 
7) Xaplanteris P, Fournier S, Pijls NHJ, et al: Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. N Engl J Med 379:250-259, 2018.
PubMed
8) Fearon WF, Collet C, Roza da Costa B, et al: A Meta-Analysis of Recent Trials Comparing Revascularization With Medical Therapy Alone in Patients With Chronic Coronary Syndrome. JACC Cardiovasc Interv 14:1388-1390, 2021.
PubMed
9) Fournier S, Kobayashi Y, Fearon WF, et al: Asymptomatic Patients With Abnormal Fractional Flow Reserve Treated With Medication Alone or With PCI. J Am Coll Cardiol 74:1642-1644, 2019.
PubMed
10) Lee JM, Choi KH, Koo BK, et al: Prognostic Implications of Plaque Characteristics and Stenosis Severity in Patients With Coronary Artery Disease. J Am Coll Cardiol 73:2413-2424, 2019.
PubMed
11) Norgaard BL, Leipsic J, Gaur S, et al: Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). J Am Coll Cardiol 63:1145-1155, 2014.
 
12) Danad I, Szymonifka J, Twisk JWR, et al: Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a meta-analysis. Eur Heart J 38:991-998, 2017.
PubMed
13) Douglas PS, De Bruyne B, Pontone G, et al: 1-Year Outcomes of FFRCT-Guided Care in Patients With Suspected Coronary Disease: The PLATFORM Study. J Am Coll Cardiol 68:435-445, 2016.
PubMed
14) 日本循環器学会ホームページ:日本循環器学会/日本心臓血管外科学会合同ガイドライン 安定冠動脈疾患の血行再建ガイドライン(2018年改訂版), 2019. https://www.j-circ.or.jp/cms/wp-content/uploads/2018/09/JCS2018_nakamura_yaku.pdf
 
15) JEscaned J, Collet C, Ryan N, et al: Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. Eur Heart J 38:3124-3134, 2017.
 
16) Head SJ, Davierwala PM, Serruys PW, et al: Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Eur Heart J 35:2821-2830, 2014.
PubMed
17) Fearon WF, Zimmerman FM, De Bruyne B, et al: Fractional flow reserve-guided PCI as compared with coronary bypass surgery. N Engl J Med 386:128-137, 2022.
 
18) Al-Lamee R, Thompson D, Dehbi HM, et al: Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomized controlled trial. Lancet 391:31-40, 2018.
PubMed
19) Ford TJ, Stanley B, Sidik N, et al: 1-Year outcomes of angina management guided by invasive coronary function testing (CorMicA). JACC Cardiovasc Interv 13:33-45, 2020.
PubMed
P.1148 掲載の参考文献
1) Braunwald E, Antman EM, Beasley JW, et al: ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 36:970-1062, 2000.
 
2) The Joint European Society of Cardiology/American College of Cardiology Committee: Myocardial infarction redefined-A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36:959-969, 2000.
 
3) Ishihara M, Nakao K, Ozaki Y, et al: Long-term outcomes of non-ST-elevation myocardial infarction without creatine kinase elevation-the J-MINUET study. Circ J 81:958-965, 2017.
 
4) Kawano H, Soejima H, Kojima S, et al: Sex differences of risk factors for acute myocardial infarction in Japanese patients. Circ J 70:513-517, 2006.
PubMed
5) Nakamura Y, Yamamoto T, Okamura T, et al: Combined cardiovascular risk factors and outcome: NIPPON DATA80, 1980-1994. Circ J 70:960-964, 2006
PubMed
6) 日本循環器学会ホームページ:2017-2018年度活動 急性冠症候群診療ガイドライン(2018年改訂版), 2019. https://www.j-circ.or.jp/cms/wp-content/uploads/2018/11/JCS2018_kimura.pdf
 
7) Antman EM, Cohen M, Bernink PJ, et al: The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 284:835-842, 2000.
 
8) Fox KA, Dabbous OH, Goldberg RJ, et al: Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 333:1091, 2006.
PubMed
9) Nakatani D, Sakata Y, Suna S, et al: Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am J Cardiol 111:457-464, 2013.
 
P.1156 掲載の参考文献
1) Kimura T, Morimoto T, Nakagawa Y, et al: Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 119:987-995, 2009.
PubMed
2) Kimura T, Morimoto T, Nakagawa Y, et al: Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 125:584-591, 2012.
 
3) Natsuaki M, Morimoto T, Yamamoto E, et al: One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther 31:196-209, 2016.
PubMed
4) Watanabe H, Domei T, Morimoto T, et al: Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA 321:2414-2427, 2019.
 
5) Watanabe H, Domei T, Morimoto T, et al: Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk: Insight From the STOPDAPT-2 Trial. Circulation 140:1957-1959, 2019.
PubMed
6) Watanabe H, Morimoto T, Natsuaki M, et al: Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol 7:407-417, 2022.
PubMed
7) PCR online: STOPDAPT-3: an aspirin-free antithrombotic strategy for percutaneous coronary intervention, Reported from ESC Congress 2023. https://www.pcronline.com/News/Whats-new-on-PCRonline/2023/ESC/STOPDAPT-3-aspirin-free-antithrombotic-strategy-percutaneous-coronary-intervention
 
8) Dewilde WJ, Oirbans T, Verheugt FW, et al: Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:1107-1115, 2013.
PubMed
9) Lopes RD, Hong H, Harskamp RE, et al: Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. JAMA Cardiol 4:747-755, 2019.
PubMed
10) Matsumura-Nakano Y, Shizuta S, Komasa A et al: Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation. Circulation 139:604-616, 2019.
PubMed
11) Yasuda S, Kaikita K, Akao M et al: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med 381:1103-1113, 2019.
PubMed
12) Okumura K, Akao M, Yoshida T et al. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. N Engl J Med 383:1735-1745, 2020.
PubMed
13) 日本循環器学会ホームページ:2019年度活動 2020年JCSガイドラインフォーカスアップデート版 冠動脈疾患患者における抗血栓療法, 2020. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Kimura_Nakamura.pdf
 
P.1163 掲載の参考文献
1) Cannon CP, Blazing MA, Giugliano RP, et al: Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 372:2387-2397, 2015.
PubMed
2) Hoogeveen RC, Gaubatz JW, Sun W, et al: Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol 34:1069-1077, 2014.
PubMed
3) Yamashita S, Masuda D, Matsuzawa Y: Pemafibrate, a New Selective PPARalpha Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. Curr Atheroscler Rep 22:5-21, 2020.
PubMed
4) Pradhan AD, Glynn RJ, Fruchart JC, et al: Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med 387:1923-1934, 2022.
 
5) Yokoyama M, Origasa H, Matsuzaki M, et al: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369:1090-1098, 2007.
PubMed
6) Bhatt DL, Steg PG, Miller M, et al: Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380:11-22, 2019.
PubMed
7) Nicholls SJ, Lincoff AM, Garcia M, et al: Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA 324:2268-2280, 2020.
PubMed
8) Bowman L, Mafham M, Wallendszus K, et al: Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med 379:1540-1550, 2018.
 
9) Manson JE, Cook NR, Lee I, et al: Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med 380:23-32, 2019.
 
10) Kodera S, Morita H, Kiyosue A, et al: Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan. Circ J 82:2602-2608, 2018.
PubMed
11) Abifadel M, Varret M, Rabes J-P, et al: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154-156, 2003.
PubMed
12) Cohen JC, Boerwinkle E, Mosley Jr TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264-1272, 2006.
 
13) Kiyosue A, Honarpour N, Kurtz C, et al: A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. Am J Cardiol 117:40-47, 2016.
 
14) Sabatine MS, Giugliano RP, Keech AC, et al: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 376:1713-1722, 2017.
PubMed
15) Schwartz GG, Steg PG, Szarek M, et al: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 379:2097-2107, 2018.
PubMed
16) Hirayama A, Yamashita S, Kiyosue A, et al: Long-Term Treatment With Evolocumab Among Japanese Patients-Final Report of the OSLER Open-Label Extension Studies. Circ J 83:971-977, 2019.
PubMed
17) O'Donoghue ML, Giugliano RP, Wiviott SD, et al: Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. Circulation 146:1109-1119, 2022.
PubMed
18) Kodera S, Morita H, Kiyosue A, et al: Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan. Circ J 82:2602-2608, 2018.
PubMed
19) Wright RS, Ray KK, Raal FJ, et al: Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol 77:1182-1193, 2021.
 
20) Fitzgerald K, White S, Borodovsky A, et al: A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 376:41-51, 2017.
PubMed
21) Cordero A, Santos-Gallego CG, Facila L, et al: Estimation of the major cardiovascular events prevention with Inclisiran. Atherosclerosis 313:76-80, 2020.
PubMed
22) Lekuona I, Pinto X: Clinical development of bempedoic acid: phase 2 and phase 3 clinical trials. Clin Investig Arterioscler 33(Suppl 1):58-64, 2021.
 
23) Nissen SE, Lincoff AM, Brennan D, et al: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med 388:1353-1364, 2023.
PubMed
P.1170 掲載の参考文献
1) 日本循環器学会, 日本糖尿病学会(監), 日本循環器学会・日本糖尿病学会 合同委員会(編):糖代謝異常者における循環器病の診断・予防・治療に関するコンセンサスステートメント, 2020.
 
2) Vaduganathan M, Mensah GA, Turco JV, et al: The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J Am Coll Cardiol 80:2361-2371, 2022.
 
3) Samuel VT, Shulman GI: Mechanisms for insulin resistance: common threads and missing links. Cell 148:852-871, 2012.
PubMed
4) Ahmad E, Lim S, Lamptey R, et al: Type 2 diabetes. Lancet 400:1803-1820, 2022.
PubMed
5) Bjorkegren JLM, Lusis AJ: Atherosclerosis: Recent developments. Cell 185:1630-1645, 2022.
PubMed
6) Bornfeldt KE: Does Elevated Glucose Promote Atherosclerosis? Pros and Cons. Circ Res 119:190-193, 2016.
PubMed
7) Libby P: The changing landscape of atherosclerosis. Nature 592:524-533, 2021.
PubMed
8) ElSayed NA, Aleppo G, Aroda VR, et al: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care 46:S158-S190, 2023.
 
9) Zelniker TA, Wiviott SD, Raz I, et al: Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation 139:2022-2031, 2019.
PubMed
10) Palmer SC, Tendal B, Mustafa RA, et al: Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 372:m4573, 2021.
PubMed
11) Davies MJ, Aroda VR, Collins BS, et al: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45:2753-2786, 2022.
 
12) 坊内良太郎, 近藤龍也, 太田康晴, 他:2型糖尿病の薬物療法のアルゴリズム. 糖尿病 65:419-434, 2022.
 
13) Neves JS, Borges-Canha M, Vasques-Novoa F, et al: GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes. J Am Coll Cardiol 82:517-525, 2023.
PubMed
14) Husain M, Birkenfeld AL, Donsmark M, et al: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 381:841-851, 2019.
PubMed
15) Brown E, Heerspink HJL, Cuthbertson DJ, et al: SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 398:262-276, 2021.
PubMed
P.1176 掲載の参考文献
1) Schumann CL, Mathew RC, Dean JL, et al: Functional and economic impact of INOCA and influence of coronary microvascular dysfunction. JACC Cardiovasc Imaging 14:1369-1379, 2021.
PubMed
2) Kunadian V, Chieffo A, Camici PG, et al: An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J 41:3504-3520, 2020.
 
3) Perera D, Berry C, Hoole SP, et al: Invasive coronary physiology in patients with angina and non-obstructive coronary artery disease: a consensus document from the coronary microvascular dysfunction workstream of the British Heart Foundation/National Institute for Health Research Partnership. Heart 109:88-95, 2022.
PubMed
4) 日本循環器学会/日本心血管インターベンション治療学会/日本心臓病学会合同ガイドライン:2023年JCS/CVIT/JCCガイドライン フォーカスアップデート版 冠攣縮性狭心症と冠微小循環障害の診断と治療, 2023.
 
5) Mileva N, Nagumo S, Mizukami T, et al: Prevalence of coronary microvascular disease and coronary vasospasm in patients with nonobstructive coronary artery disease: systematic review and meta-analysis. J Am Heart Assoc 11:e023207, 2022.
 
6) Shimokawa H, Suda A, Takahashi J, et al: Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. Eur Heart J 42:4592-4600, 2021.
 
7) Ford TJ, Stanley B, Sidik N, et al: 1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). JACC Cardiovasc Interv 13:33-45, 2020.
PubMed

【臨床報告】

P.1186 掲載の参考文献
1) Incalzi RA, Gemma A, Capparella O, et al: Energy intake and in-hospital starvation. A clinically relevant relationship. Arch Intern Med 156:425-429, 1996.
PubMed
2) 前田憲男, 吉岡毅, 甄立学, 他:高齢者の食欲不振. 医学と薬学 71(5):831-840, 2014.
Medical*Online
3) Antonelli Incalzi R, Landi F, Cipriani L, et al: Nutritional assessment: a primary component of multidimensional geriatric assessment in the acute care setting. J Am Geriatr Soc 44:166-174, 1996.
PubMed
4) Landi F, Zuccala G, Gambassi G, et al: Body mass index and mortalityamong older people living in the community. J Am Geriatr Soc 47:1072-1076, 1999.
 
5) Cederholm T, Jagren C, Helistrom K: Outcome of protein-energy malnutrition in elderly medical patients. Am J Med 98:67-74, 1995.
 
6) Gavazzi G, Krause K-H: Ageing and infection. Lancet Infect Dis 2:659-666, 2002.
PubMed
7) 吉田貞夫:回復期リハビリテーション病棟に入院する高齢者の栄養状態とアウトカム. 静脈経腸栄養 28(5):1051-1056, 2013.
 
8) 宮田剛:CONUT. 外科と代謝 49(4):189-190, 2015.
 
9) 厚生労働省:平成26年 国民健康・栄養調査報告
 
10) Uto NS, Amitani H, Atobe Y, et al: Herbal medicine Ninjin'yoeito in the treatment of sarcopenia and frailty. Front Nutr 5:126, 2018.
PubMed
11) Goswami C, Dezaki K, Wang L, et al: Ninjin-yoeito activates ghrelin-responsive and unresponsive NPY neurons in the arcuate nucleus and counteracts cisplatin-induced anorexia. Neuropeptides 75:58-64, 2019.
PubMed
12) Miyamoto A, Asai K, Kadotani H, et al: Ninjin'yoeito Ameliorates Skeletal Muscle Complications in COPD Model Mice by Upregulating Peroxisome Proliferator-Activated ReceptorγCoactivator-1α Expression. Int J Chron Obstruct Pulmon Dis 27(15):3063-3077, 2020.
 
13) 藤田日奈, 村田健太:人参の抗うつ作用および疲労に対する効果. phil漢方 65:24-25, 2017.
 
14) Takeda H, Sadakane C, Hattori T, et al: Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterogy. 134(7):2004-2013, 2008.
 
15) Ito A, Shin N, Tsuchida T, et al: Antianxiety-Like Effects of Chimpi (Dried Citrus Peels) in the Elevated Open-Platform Test. Molecules 18(8):10014-10023, 2013.
PubMed
16) Kim Y, Yoo S, Chae C, et al: Omija Fruit Extract Improves Endurance and Energy Metabolism by Upregulating PGC-1α Expression in the Skeletal Muscle of Exercised Rats. Journal of Medicinal Food 17(1):28-35, 2014.
 
17) 片山一朗, 他:皮膚症状を有するシェーグレン症候群患者における人参養栄湯の皮膚疾患特異的QOL改善効果の検討. 西日本皮膚科 70(5):516-521, 2008.
 
18) 鈴木伸一, 粟飯原史孝, 柴原美穂, 他:クラシエ人参養栄湯エキス細粒特定使用成績調査-高齢者に対する使用実態下での安全性および有効性の検討-. 医学と薬学 74(10):1285-1297, 2017.
 

【臨床試験】

P.1202 掲載の参考文献
1) レブラミド(R)カプセル2.5mg/5mg 医薬品インタビューフォーム. ブリストル・マイヤーズ スクイブ株式会社. 2023年4月改訂(第17版)
 
2) RevMate(R)(レブラミド(R)・ポマリスト(R)適正管理手順). ブリストルマイヤーズスクイブ株式会社. 2021年7月改訂(Ver. 6.2)
 
3) 後発医薬品の生物学的同等性試験ガイドライン等の一部改正について(令和2年3月19日付け薬生薬審発0319第1号 厚生労働省医薬・生活衛生局医薬品審査管理課長)
 

【Diagnosis】

P.1210 掲載の参考文献
1) Ferlay J, Colombet M, Soerjomataram I, et al: Cancer statistics for the year 2020: An overview. Int J Cancer 149(4):778-789, 2021.
 
2) El-Serag H, Rudolph K: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557-2576, 2007.
PubMed
3) Sakamoto M: Early HCC: diagnosis and molecular markers. J Gastroenterol 44:108-111, 2009.
PubMed
4) Yu S: A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol 22(1):7-17, 2016.
 
5) 肝癌診療ガイドライン2021 日本肝臓学会(監), 「肝癌診療ガイドライン」日本肝臓学会(編), 金原出版, 東京, 2021.
 
6) Atiq O, Tiro J, Yopp A, et al: An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology 65(4):1196-1205, 2017.
PubMed
7) Chen L, Ho D, Lee N, et al: Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Ann Surg Oncol 17(9):2518-2525, 2010.
 
8) Kudo M, Matsui O, Izumi N, et al: Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update. Oncology 87(Suppl 1):7-21, 2014.
 
9) Kondo Y, Kimura O, Shimosegawa T: Significant biomarkers for the management of hepatocellular carcinoma. Clin J Gastroenterol 8(3):109-115, 2015.
PubMed
10) Omata M, Cheng AL, Kokudo N, et al: Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317-370, 2017.
 
11) Capurro M, Wanless IR, Sherman M, et al: Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastoroenterology 125(1):89-97, 2003.
 
12) International Consensus Group for Hepatocellular Neoplasia: Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49:658-664, 2009.
 
13) Filmus J, Capurro M: Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J 280:2471-2476, 2013.
 
14) Nojima H, Nishii T, Iida K, et al: Elucidation of the Usefulness of Glypican-3, a Hepatocellular Carcinoma Biomarker, with the Fully Automated LUMIPULSE(R) System. BPB Reports 6:21-26, 2023.
 
15) Nishizono I, Iida S, Suzuki N, et al: Rapid and sensitive chemiluminescent enzyme immunoassay for measuring tumor markers. Clin Chem. 37(9):1639-1644, 1991.
PubMed
16) Rumgay H, Arnold M, Ferlay J, et al: Global burden of primary liver cancer in 2020 and predictions to 2040. Journal of Hepatology 77(6):1598-1606, 2022.
PubMed
17) Luo P, Wu S, Yu Y, et al: Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Pathology and Oncology Research 26(2):599-603, 2020.
 
18) Feng H, Li B, Li Z, et al: PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer 21(1):2021.
 
19) Metz CN, Brunner G, Choi-Muira NH, et al: Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D. EMBO J 13(7):1741-1751, 1994.
PubMed
20) Hippo Y, Watanabe K, Watanabe A, et al: Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res. 64(7):2418-2423, 2004.
PubMed
21) Nakatsura T, Nishimura Y: Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 19:71-77, 2005.
 
22) Shimizu Y, Suzuki T, Yoshikawa T, et al: Next-Generation Cancer Immunotherapy Targeting Glypican-3. Front. Oncol 10:248, 2019.
 

書評

最近チェックした商品履歴

Loading...